IV Iron Replacement Therapy to Mitigate the Burden of Iron Deficiency Anemia: Updates for Health-System Pharmacists

This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.

Program Description

Iron deficiency anemia (IDA) occurs when iron deficiency is severe enough to diminish erythropoiesis and cause the development of anemia. IDA, a microcytic anemia is the most common cause of anemia worldwide, and its management includes identification and treatment of the underlying cause, if feasible, and iron supplementation. Though many patients with IDA can be treated with oral iron replacement agents, some cases warrant the use of intravenous (IV) iron, especially in adults who cannot tolerate or absorb oral iron. Pharmacists within health systems and hospitals must recognize risk factors and clinical presentation of IDA. This activity will review the challenges associated with identifying and treating IDA, especially in patient populations at greater risk for health complications. With a greater understanding of available and emerging oral and IV iron formulations, pharmacists will be better equipped to discuss the benefits and risks of each, including efficacy and safety, with patient populations that are ideal candidates for IV iron replacement therapies.

Target audience: Health-system pharmacists

Type of activity: Application
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the burden of illness associated with iron deficiency anemia (IDA) including the impact of undiagnosed and untreated IDA
• Examine the safety and efficacy of current intravenous iron preparations, as well as differentiating dosing
• Determine individualized treatment strategies for patients with IDA based on clinical evidence and recommendations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-621-H01-P. The activity is available for CE credit through December 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Christopher Elder, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Advisory Boards: Pharmacosmos, Bristol Myers Squibb, Mirati, Genentech, and Pfizer.

Thaddeus McGiness, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Medical Reviewer: Geoffrey C. Wall, PharmD, BCPS, FCCP, has the following relevant financial relationship with a commercial interest to disclose:

• Speakers Bureau: Janssen Pharmaceuticals

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms